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Introduction 
Thyroid cancer, excluding ovarian cancer, is the most
common endocrine malignancy with the highest mor-
tality (1), so it has generated considerable debate and vo-
luminous literature from endocrinologists, surgeons, and
nuclear physicians. However, controversy continues re-
garding the optimal management of patients with dif-
ferentiated thyroid cancer because no prospective ran-
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Thyroid cancer is the most common endocrine malignancy with the
highest mortality, so it has generated considerable debate and volumi-
nous literature by endocrinologists, surgeons, and nuclear physicians. If
total thyroidectomy is the primary treatment for patients with differen-
tiated thyroid cancers (DTC) and it has proven to be effective and sa-
fe, the extent of lymph nodes dissection remains controversial among ex-
perts in the field. This controversy persists largely due to the lack of a
prospective randomized controlled trial to define whether the addition
of central lymph node dissection (CLND) to total thyroidectomy for pa-
pillary thyroid cancer (PTC) confers an increased risk of permanent hy-
poparathyroidism and permanent nerve injury. According to the Con-
sensus Conference of the UEC’s Club therapeutic modified radical neck
dissection (MRND) should be performed only in the patients with evi-
dence of neoplastic multiple lymph node involvement. Although central
lymph node dissection may increase the risk of hypoparathyroidism and
nerve injury when compared with total thyroidectomy without CLND,
it may decrease recurrence of PTC and likely improves disease specific
survival and offers a sufficient alternative to routine prophylactic mo-
dified radical neck dissection. Selective central lymph node dissection
should be performed, under the care of experienced surgeons, in high ri-
sk patients (50 years or older aged, large tumor expansion within the
thyroid, or with extrathyroid extension), with the extension to the sta-
tion II-III-IV in case of single lymph node involvement. 
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Il cancro della tiroide è la più comune neplasia maligna endocri-
na con la più alta mortalità. La tiroidectomia totale è il trattamento
primario per pazienti con cancro differenziato della tiroide (DTC) e si
è dimostrata efficace e sicura. L’estensione della dissezione linfonodale
rimane controversa tra esperti nel campo.Questa controversia persiste
largamente anche per la mancanza di uno studio prospettico controlla-
to randomizzato che riconosca come la  dissezione linfonodale centrale
(CLND) per cancro papillare della tiroide (PTC) conferisca alla tiroi-
dectomia totale un aumentato rischio di ipoparatiroidismo e di lesione
ricorrenziale permanente. Secondo la Consensus Conference del  UEC’s
Club la dissezione radicale terapeutica modificata del collo (MRND)
dovrebbe essere eseguita solo in pazienti con evidenza di coinvolgimen-
to lonfonodale neoplastico multiplo. Sebbene la dissezione linfonodale
centrale possa aumentare il rischio di ipoparatiroidismo e di lesione del
ricorrente a confronto con la tiroidectomia totale senza CLND, essa
può ridurre le metastasi da PTC e probabilmente migliorare la soprav-
vivenza specifica della malattia. Offre inoltre un’alternativa sufficien-
te alla dissezione radicale profilattica modificata del collo. La dissezio-
ne linfonodale centrale selettiva deve essere eseguita da mani esperte, in
pazienti ad alto rischio (maggiori di 50 anni, larga diffusione del tu-
more intra o extratiroidea), con l’estensione alle stazioni II-III-IV in
caso di coinvolgimento linfonodale singolo in esse.
Differentiated thyroid cancer: role of the lymph node dissection
P. CAGLIÀ, E. ZAPPULLA, S. COSTA, A. TRACIA, M. VEROUX, V. RUSSO, L. BORZÌ, 
B. LUCIFORA, G. PATANÈ, L. TRACIA, C. AMODEO
G Chir Vol. 31 - n. 6/7 - pp. 293-295
Giugno-Luglio 2010
293
University of Catania, Catania, Italy 
Department of Surgical Sciences, Organ Transplantation 
and Advanced Technologies 
Surgery Oncology Unit
(Head: Prof. C. Amodeo)
Relazione presentata in occasione del "XXIX Congresso Nazionale 
della Società Italiana di Endocrinochirurgia"
Palermo, 24-26 giugno 2010
© Copyright 2010, CIC  Edizioni Internazionali, Roma
KEY WORDS: Differentiated thyroid cancer - Lymph node dissection.
Cancro differenziato della tiroide - Dissezione linfonodale.
294
P. Caglià et al.
domized studies assess the merits of diagnostic evalua-
tion, extent of surgery, postoperative adjuvant therapy
and follow-up. If total thyroidectomy is the primary treat-
ment for patients with differentiated thyroid cancers
(DTC) and it has proven to be effective and safe, the ex-
tent of lymph nodes dissection remains controversial
among experts in the field.  This controversy persists lar-
gely due to the lack of a prospective randomized con-
trolled trial to define whether the addition of central
lymph node dissection (CLND) to total thyroidectomy
for papillary thyroid cancer (PTC) confers an increased
risk of permanent hypoparathyroidism and permanent
nerve injury.  Thyroid cancer is divided into differentiated
and another group. The differentiated thyroid cancers
derives from follicular epithelial cells and includes pa-
pillary, follicular, Hürthle cell and a mixed variety. The
other group includes medullary carcinoma, lymphoma,
anaplastic cancer and certain rare varieties such as sar-
coma or metastatic tumours. Papillary and follicular car-
cinoma represent almost 90% of the thyroid malignancies,
being responsible for 70% of the mortality generated by
thyroid cancer (2). Papillary thyroid cancer is the most
common endocrine malignancy (3); it is also one of the
most curable human cancers, with a 5-year survival rate
of 95%. While the follicular carcinoma has more of a pro-
pensity to metastasize hematogenously to the lungs and
bones, papillary carcinoma usually shows mild charac-
teristics, and it metastasizes and shows recurrence to the
lymph node in high incidence. Cervical lymph node me-
tastases are quite common in papillary thyroid cancer and
are present in 20%–50% of patients (4).
Discussion 
The surgical treatment of cervical lymph nodes in
DTC remains controversial. It has been traditionally ac-
cepted that regional lymph node metastases in PTC may
increase local recurrence rates but do not affect survival.
This conventional wisdom has been challenged by recent
reports indicating that regional lymph node metastases
are the cause of increase mortality. Thus, there has been
renewed interest in operative control of nodal disease for
PTC (3). Although thyroid cancer is the only human can-
cer in which the presence of lymph node metastasis has
no major implication on the overall prognosis (5), a wor-
se prognosis was correlated with papillary carcinoma de-
monstrating two or more of the following four charac-
teristics; male gender, age 55 years or older, maximal tu-
mour diameter larger than 3 cm, and massive extrathy-
roid extension (6).
The management protocols in thyroid surgery have
been reviewed and updated by Consensus Conference
called on the topic by the Italian Association of Endo-
crine Surgery Units (UEC Club) which provides the ra-
tionale of the thyroid patient management (7). When
neck dissection is recommended it can be performed as
prophylactic or therapeutic lymph node dissection. The
term ‘‘prophylactic’’ denotes removal of lymph nodes that
are deemed normal pre-or intraoperatively by palpation
or imaging studies (8). ‘‘Therapeutic’’ dissection deno-
tes removal of lymph nodes that likely contain metastatic
disease based on palpation, imaging studies or pathological
data (9, 10). 
According to the Academy’s Committee for head and
neck surgery and oncology, (11) the classification of neck
dissection includes: radical neck dissection (RND) and
extended radical neck dissection (ERND), modified ra-
dical neck dissection (MRND), selective neck dissection
(SND). Radical neck dissection and extended radical neck
dissection are the more extended dissection of the
neck’s lymphatic and nonlymphatic structures. Modified
radical neck dissection preserves nonlymphatic structures
of the neck. Selective neck dissection denotes removal
of only one or more groups of lymph nodes. How wi-
dely accepted we consider the classification by the Ame-
rican Academy of Head and Neck Surgery in six levels
and sublevels (12). Particularly, the level VI nodes lies
in a central position in the neck. Nodes in level VI cor-
respond to those in the central neck compartment and
are, in a high percentage of cases, the elective localiza-
tion  of the metastases (8). Its superior border is the hyoid
bone, the inferior border is the suprasternal notch, and
the lateral borders are the common carotid arteries. Le-
vel VI lymph nodes include pretracheal and paratracheal
nodes, the precricoid node, and the perithyroidal nodes,
including nodes along the recurrent laryngeal nerves. One
kind of selective neck dissection denotes removal of the
VI level’s nodes. Complications of total thyroidectomy
include permanent hypoparathyroidism and permanent
nerve injury. Exactly, total thyroidectomy without
lymph node dissection, performed by experienced sur-
geons, results in permanent hypoparathyroidism in 1%–
2% of patients and permanent nerve injury (recurrent
laryngeal, external branch of the superior laryngeal) in
1%–2% of patients (13,14). Actually, there is no con-
sensus about the risk of these complications after cen-
tral lymph node dissection. Multiple case series attempted
to address this topic (15-17), but the best available data
are provided by two prospective and two retrospective
cohort studies (18,19). No prospective, randomized stu-
dies exist to define whether the addition of CLND to
total thyroidectomy for PTC confers an increased risk
of permanent hypoparathyroidism and permanent ner-
ve injury.  However, Matthew L. et al. demonstrates, th-
rough a systematic review of the Literature using evidence
based criteria, that there may be a higher rate of per-
manent hypoparathyroidism and unintentional perma-
nent nerve injury when CLND is performed with total
thyroidectomy than for total thyroidectomy alone (8).
Methods
In our experience we found that the optimal treatment of the
differentiated thyroid cancer consists in the modulation of the ex-
tension of the lymph node dissection. This kind of treatment of a
tumour “biologically indolent” makes possible eventually needing
reoperations with a low morbidity if performed by experienced sur-
geons.
Then, we consider an important part of the therapeutical treat-
ment the adjuvant radioactive iodine treatment. We finally think
it is fundamental to obtain the optimal treatment to select patients
with high risk of recurrent loco-regional tumour, expression of pos-
sible distant metastasis. We recommend prophylactic central neck
node dissection only for high risk patients who present two or more
of the following four characteristics: male gender, age 55 years or
older, maximal tumour diameter more than 3 cm and massive ex-
trathyroid extension. In case of multiple lymph node involvement
we perform a functional MRND, recommending the selective cen-
tral node dissection (station VI) and of the station II-III-IV ( up-
per, medium and lower jugular) in case of single lymph node in-
volvement.
Conclusion
According to the Consensus Conference of the
UEC’s Club (7, 20) therapeutic modified radical neck
dissection (MRND) should be performed only in the pa-
tients with evidence of neoplastic multiple lymph node
involvement. Although central lymph node dissection
may increase the risk of hypoparathyroidism and nerve
injury when compared with total thyroidectomy without
CLND, it may decrease local recurrence of PTC and likely
improves disease specific survival and offers a sufficient
alternative to routine prophylactic modified radical neck
dissection. Selective central lymph node dissection
should be performed, under the care of experienced sur-
geons, in high risk patients (50 years or older aged, lar-
ge tumor expansion within the thyroid, or with ex-
trathyroid extension), with the extension to the station
II-III-IV in case of single lymph node involvement.
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